Fierce Biotech Fundraising Tracker '26: Copenhagen's Commit raises $60M; Marrow extracts $120M series B


A new year brings a fresh Fierce Biotech Fundraising Tracker designed to record the significant amount of venture capital that flows into biopharma.

We’re keeping the same guidelines used for last year’s tracker and will only include financing rounds of $50 million and above.

November

November 17—Commit Biologics
Series: seed
Amount: $60M
Investors: Ackermans & van Haaren, AbbVie Ventures, M Ventures, Bioqube Ventures, Korys and Novo Holdings

Copenhagen-based Commit Biologics raised $60 million (€54 million) in seed financing to advance its pipeline of complement-powered immune engagers toward the clinic. The financing will support IND-enabling studies and IND filing for COM002, Commit’s first development candidate, a dual-targeting bispecific complement engager molecule designed for targeted immune cell depletion for patients with cancer and autoimmune disease. The biotech spun out of Aarhus University in Denmark to develop immune engagers for autoimmune and oncology diseases. Release

November 17—Marrow Therapeutics 
Series: B
Amount: $120M
Investors: OrbiMed, Scion Life Sciences and venBio

A new biotech targeting blood disorders, aptly called Marrow Therapeutics, strengthened its financial backbone courtesy of a $120 million series B led by OrbiMed. Simultaneously, the Massachusetts-based biotech announced $54 million from a series A led by its founder Scion Life Sciences and venBio. The biotech’s lead candidate, dubbed MAR-101, uses the company’s in vivo transferrin antibody bioconjugate platform to reduce the blood cell development protein BCL11A, which underlies both target diseases. Story

November 16—Seawolf Therapeutics
Series: A
Amount: $100M
Investors: Versant Ventures, Eli Lilly, Novartis Venture Fund, MPM BioImpact, CRISPR Therapeutics, Sixty Degree Capital, Alexandria Venture Investments and the National Bleeding Disorders Foundation’s philanthropic venture arm Pathway to Cures.

Gene therapy biotech Seawolf Therapeutics has emerged from the deep with $100 million to fuel its DNA therapeutic ambitions and a $1.2 billion deal with Sanofi. Seawolf disclosed that the deal with Sanofi involves a “multi-target research collaboration and exclusive license agreement” to develop undisclosed therapies for bleeding disorders and additional unnamed indications. The San Diego-based company got its start in 2021 and has established a lead program targeting metabolic diseases. Story

November 11—Eli Radiopharma
Series: A
Amount: 400M yuan ($60M)
Investors: Huagai Capital, Bayland Capital, Boyu Ventures, Delian Capital, InnoPinnacle Fund, Haibang Venture, Bairui Capital, Shenzhen Angel FOF Management, Grand Flight Investment, CSPC & Growth Bio Fund, Huaige Capital, KHK Fund, Longfeng Venture, Hongsheng Capital, Bioclub Fund and Skyfield Capital.

The Hangzhou, China-based radiopharma has earmarked the proceeds to “support the advancement of the company’s core innovative pipeline toward clinical development.” Since being founded in 2024, Eli now has several assets aimed at “novel molecular targets” approaching IND submission. Release

November 11—Neurosterix
Series: B
Amount: $105M
Investors: “A syndicate of leading life science investors.”

The Addex Therapeutics’ spinout will use the funds to bankroll a planned phase 2 schizophrenia study of NTX-253, a highly selective muscarinic M4 positive allosteric modulator (PAM). Some of the cash will also go toward a wider pipeline of neuropyshciatric therapies, such as a mGlu7 negative allosteric modulator called NTX-819 for mood and anxiety disorders, as well as an M4 PAM called NTX-529 aimed at additional psychosis- and mood-related disorders. Story

November 11—VectorY Therapeutics
Series: NA
Amount: $83.5M
Investors: Angelini Ventures, Invest-NL, the EIB, Forbion, EQT Life Sciences, MRL Ventures, Insight Partners, BGV, Eli Lilly and the ALS Investment Fund. 

The Netherlands-based biotech will use the 74.5 million euros to advance a pipeline led by VTx-002, a vectorized antibody gene therapy being evaluated in a phase 1/2 study for amyotrophic lateral sclerosis. Cash will also go toward VTx-003 for Huntington’s disease and additional programs targeting neurodegenerative diseases. The latest financing follows a $138 million series A back in 2023. Release

November 10—Oyster Therapeutics
Series: A-2
Amount: $60M
Investors: 4BIO Capital, Eli Lilly, CE Ventures, Actium Group, TOHO Ventures, Syncona, Oxford Science Enterprises, Mission BioCapital and MGB Ventures.

Oyster Therapeutics—previously known as Kesmalea Therapeutics—will use the cash to take its oral, brain-penetrant tau protein degrader into the clinic. The London-based biotech’s lead program is a treatment for tau-driven neurodegenerative diseases such as Alzheimer’s. Oyster will also spend some of the funds on developing other protein degraders using its SELFTAC platform, which is designed to transform large bifunctional protein degraders into small molecules. Release

November 9—Delix Therapeutics
Series: C
Amount: $100M
Investors: J&J’s venture capital arm JJDC, SV Health Investors’ Dementia Discovery Fund, with participation from existing investors, RA Capital, UC Investments, Artis Ventures, OMX Ventures, Dolby Family Ventures, Bail Capital, Adage Capital Management, Hamilton Square Partners Management, Vestal Point Capital, and YK Bioventures among others.

Delix Therapeutics has raised $100 million in a series C round backed by the likes of Johnson & Johnson to advance a phase 2-ready non-hallucinatory psychedelic therapy for depression. The therapy, called zalsupindole, is a neuroplastogen designed to harness the brain’s ability to regrow lost connections, known as neuroplasticity. Delix expects to initiate a placebo-controlled phase 2b study in major depressive disorder (MDD) in the first half of 2027. The Boston biotech will also use the funds to further develop its other neuroplastogens for neurological and neurodegenerative diseases, such as substance use disorders, bipolar disorder, schizophrenia and Alzheimer’s disease. Story

November 4—Alethio Therapeutics
Series: A
Amount: $90M
Investors: Sofinnova Partners, RA Capital, Oxford Science Enterprises, Cancer Research Horizons and the University of Oxford.

The British biotech—which spun out of a lab at the University of Oxford in 2021—will use the cash to fund its next-gen therapies for a group of slow-growing blood cancers called myeloproliferative neoplasms. This includes advancing its lead program, dubbed ATX-011, through completion of phase 1/2a studies in essential thrombocythaemia up to phase 3 readiness, while also progressing additional MPN programs toward IND submission. Release
 

November 4—T Therapeutics
Series: B
Amount: $133M
Investors: Advent Life Sciences, British Business Bank, the venture capital arm of Johnson & Johnson, Samsara BioCapital, M-Ventures, Eli Lilly and Company, Sofinnova Partners, F-Prime, Digitalis Ventures, Cambridge Innovation Capital, Sanofi Ventures, Tencent and BGF.

The Cambridge, England-based company will use its Big Pharma-backed series B to take a pair of T-cell receptor CD3 bispecific candidates into the clinic. The U.K. biotech’s pipeline consists of the preclinical TTX-008, which is aimed at various tumor types, and the discovery-stage TTX-018, which is targeting inflammation. T-Therapeutics picked up a prior series A round of $59 million in 2023, which the biotech extended last year with an additional $32 million. Story

October

October 30—Setara Biosciences
Series: A
Amount: $90M
Investors: Deerfield Management, Canaan, Droia Ventures, EcoR1, Euclidean Capital and Regeneron Ventures and Jazz Pharmaceuticals

The drug programs left behind after Jazz Pharmaceuticals’ $820 million acquisition of Actio Biosciences have found a new home in Setara Biosciences, a spinout launching with $90 million in series A financing to advance its neuroscience pipeline. Setara’s pipeline will include a small molecule TRPV4 inhibitor STAR-0871, formerly ABS-0871, for Charcot-Marie-Tooth disease type 2C (CMT2C) and overactive bladder, as well as early-stage discovery programs focused on genetic forms of epilepsy and other indications, including migraine. Story

October 19—Nouscom
Series: D
Amount: $135M
Investors: M Ventures, Revelation Partners, Angelini Industries, the European Investment Bank and Italian VC firm Neva SGR, 5AM Ventures and Andera Partners.

The funding will support development of the Swiss biotech’s lead asset NOUS-209, an off-the-shelf cancer immunotherapy that targets tumors with mismatch repair deficiency and microsatellite instability. Story

October 16—Estuary Biotherapeutics
Series: A
Amount: $93M
Investors: RA Capital Management, Deep Track Capital, Biogen New Ventures, UPMC Enterprises, Pivotal bioVenture Partners, the National Kidney Foundation Innovation Fund, a family office connected to an individual living with autosomal dominant polycystic kidney disease (ADPKD), 4BIO Capital and GV.

Estuary’s series A, combined with $10 million in seed funding, meant the biotech emerged from stealth with $103 million on hand to power a pair of gene therapies into clinical trials for an inherited kidney disorder. Story
 

October 15—OMass Therapeutics
Series: C
Amount: $310M
Investors: GV, Bain Capital Life Sciences, Forbion, Novo Holdings, Janus Henderson Investors, SV Health Investors, Jefferson Life Sciences, Syncona, Sanofi Ventures, the U.K. government’s British Business Bank and the University of Oxford

British biotech OMass will channel its new series C funds toward taking its lead candidate—a melanocortin-2 receptor antagonist dubbed OMS1620—through an ongoing phase 1 study and into phase 2 development in congenital adrenal hyperplasia (CAH) and ACTH-dependent Cushing’s syndrome. The Oxford, U.K.-based startup has hopes to become “Britain’s Big Biotech,” as the U.K. has not seen a success story in the space on the scale of those written by Vertex or Genentech. The biotech’s fundraising history includes a $100 million series B from 2022 that was topped off with another 10 million pounds sterling in 2023. Story

October 13—Soufflé Therapeutics
Series: B
Amount: $135M
Investors: Juvia Group, TCG Crossover Management, BB Biotech, Fidelity Management & Research Company, Balyasny Asset Management, a Leading Sovereign Wealth Fund, Amgen Ventures, ARCH Venture Partners, Bessemer Venture Partners, Breyer Capital, The Invus Group, Janus Henderson, Leaps by Bayer, Polaris Partners, Safar Partners, TAS Partners, Temasek and Vida Ventures

Soufflé has risen even further, following a $200 million series A when the Boston biotech emerged from stealth in October 2025. The oligonucleotide therapy startup is a Langer family affair, with Moderna maverick Robert Langer co-founding the company and his daughter Susan serving as founding president and chief business officer. The latest funds will support the progress of Soufflé’s three lead programs into clinical studies, the most advanced of which is aimed at facioscapulohumeral muscular dystrophy. Release

October 7—Matchpoint Therapeutics
Series: B
Amount: $150M
Investors: Nextech Invest, Norwest, Invus, BB Biotech, T1D Fund, BOLD Longevity Growth, Access Biotechnology, Atlas Venture, Sanofi Ventures and Digitalis Ventures

The top spending priority for the series B funds will be taking MPT-062 into the clinic next year. MPT-062 is an oral T cell modulator that the biotech has been pitching as a first-in-class option to treat autoimmune and inflammatory diseases. Some money will also be set aside to advance Matchpoint’s “broader product pipeline”—although details remain under wraps for now. Story

October 6—KymaThera
Series: B
Amount: $80M
Investors: Alta Partners, Venrock, Foresite Capital, J. Wood Capital and others

The cash infusion will directly support the San Diego biotech’s PI3Kα inhibitor K-1728, with a phase 1 trial planned to start dosing by the end of the year. The money should last through clinical proof-of-concept, and KymaThera plans to explore K-1728 as both a monotherapy and in combinations for HR+/HER2- breast cancer. Release

October 6—RougeTx
Series: A
Amount: $58M
Investors: BioGeneration Ventures, Angelini Ventures, Kurma Partners, Epidarex Capital, Vesalius Biocapital Partners, ROM Utrecht Region, p53 Invest and Kerna Ventures.

A new Dutch biotech has entered the world with plans to treat an inherited bleeding disorder called hereditary hemorrhagic telangiectasia. A spinout from Leiden University Medical Center, RougeTx will use the funds to push lead candidate RTX-001 into clinical development while also building up its small molecule vascular biology platform periSCOPE. Release

October 1—TriGemX Bio
Series: N/A
Amount: $94M
Investors: The Column Group, TCGX, Viking Global Investors and others.

Kallyope announced its new name, TriGemX Bio, along with a $94 million financing that will be used to advance the clinical development of the company’s lead program, elismetrep, an oral TRPM8 channel blocker currently in phase 3 trials for the acute treatment of migraine. The new name is a reference to the trigeminal ganglion, a migraine-relevant neural structure where TRPM8 is expressed. Elismetrep reduced migraine pain and associated symptoms in a phase 2b trial and was well tolerated. TriGemX is currently running a pivotal phase 3 study and a long-term safety study of elismetrep and plans to launch a second pivotal trial this month. Release

September

September 30—AnaCardio
Series: B
Amount: €62.5M ($70.9M)
Investors: Novo Holdings, the Ljungström family office, Helsinn, Pureos Bioventures, Sound Bioventures, Industrifonden, Flerie, LLD Nybohov Invest AB and Innovestor Life Science.

The Swedish biotech will use the funds to advance its oral calcium-sensitizing contractile agent, AC01, through phase 2b development in patients with chronic advanced heart failure with reduced ejection fraction, with the aim of establishing a phase 3-ready asset by 2028. AnaCardio was founded in 2017 out of the Karolinska Institutet and has raised around $114 million to date. Release

September 29—Breye
Series: A
Amount: $76.5M (€67.5M)
Investors: Mission BioCapital, Novo Holdings, Sound Bioventures, Ljungström family office, Innovestor Life Science, EIFO, Catalyze Capital, Modi Ventures and Pappas Capital

Novo-backed Breye Therapeutics closed an oversubscribed €67.5 million ($76.5 million) series A round to position the biotech advance its lead asset into phase 2 trials. The Copenhagen-based biotech is developing an oral small molecule to protect against retinal capillary breakdown and vascular leakage caused by chronically high glucose levels in non-proliferative diabetic retinopathy (NPDR). Breye was launched in November 2022 with a €4 million backing from Novo Holdings and Sound Bioventures. Release

September 23—Enveda
Series: E
Amount: $311M
Investors: Catalio Capital Management, Durable Capital Partners, ICONIQ, Lightspeed, Surveyor Capital (a Citadel company), Digitalis Ventures, a notable Sovereign Wealth Fund, and Alderline Group, Baillie Gifford, Premji Invest, FPV Ventures, True Ventures, Kinnevik, Dimension, Lifeforce Capital and Lux Capital

Enveda’s latest $311 million raise will position the nature-derived drug discovery company to continue growing its model, which taps organisms for novel chemistry. The latest round follows annual raises that included a $130 million series C round in November 2024 and a $150 million series D round in September 2025. The cash flow has helped the company deliver clinical data on two drug candidates this year and begin testing a third molecule in humans. The company’s assets are aimed at patients with eczema, atopic dermatitis and asthma. Story

September 23—Basecamp Research
Series: C
Amount: $140M
Investors: S32, Anthropic’s Anthology Fund, Catalio Capital Management, European Tech Collective, Firebrand River Capital, Inception Fund, King Philanthropies, NATO Innovation Fund, NVIDIA, PostScriptum, Redalpine, The Rockefeller Foundation, Singular, Sovereign AI and True Ventures

Basecamp Research has raised an oversubscribed round to finance a new generation of its proprietary EDEN model and advance its pipeline of AI-designed therapeutics toward the clinic. EDEN is an in vivo cell therapy model designed to reprogram a patient’s cells inside the body. This model is trained on the company’s so-called Trillion Gene Atlas, a genomic dataset collected through partnerships in more than 30 countries. Basecamp’s pipeline includes preclinical cell, gene and peptide therapies focused on oncology, autoimmune disease, liver disease and diabetes. Release

September 16—Sling Therapeutics
Series: C
Amount: $123M
Investors: Forbion, TPG Life Sciences Innovations and Sectoral Asset Management.

Sling Therapeutics will use the funds to advance its oral therapy, linsitinib, for thyroid eye disease (TED) through a phase 3 trial and, if successful, into commercialization. Linsitinib was originally developed by Japanese pharma Astellas as a cancer treatment, but Sling licensed the therapy in 2022, while securing a $35 million series A to run a phase 2b trial of the drug in TED. Story

September 16—Circle Pharma
Series: E
Amount: $92.5M
Investors: The Column Group, Nextech Invest, RA Capital Management, Euclidean Capital and Eli Lilly and Company.

The Bay Area biotech founded in 2012 with seed funding from Pfizer, is focused on developing therapies targeted at cyclins, key regulators of the cell cycle that are implicated in many cancers. The funds from this financing round will drive the advancement of CID-165, Circle’s oral macrocyclic cyclin D1 RxL inhibitor, through early clinical development for ER-positive breast cancer. Release

September 15—RegCell
Series: A and grant funding
Amount: $66M
Investors: Playground Global, Global Brain, Mitsui Chemicals, LG Technology Ventures, Alumni Ventures, Medical Incubator Japan, Fast Track Initiative, The University of Tokyo Edge Capital Partners, Osaka University Venture Capital, Kyoto iCAP and Japan’s Agency for Medical Research and Development.

Founded on the back of Nobel-winning regulatory T cell science, RegCell will use the raise to push its epigenetically reprogrammed Tregs into the clinic for autoimmune diseases. The company has secured a grant from Japan’s Agency for Medical Research and Development worth about $22 million, in addition to a $44 million series A. Release

September 9—Encoded Therapeutics
Series: F
Amount: $275M
Investors: Google Ventures, another healthcare fund, ARCH Venture Partners, Braidwell LP, Farallon Capital Management, Illumina Ventures, Invus, Janus Henderson Investors, Matrix Capital Management, Nolan Capital, RTW Investments, SoftBank Vision Fund 2 and Venrock.

The neuro-focused company will use the series F to support its Dravet syndrome asset and scale up its internal manufacturing capabilities. The proceeds will support a pivotal study of the asset, ETX101, in infants and young children with SCN1A-positive Dravet syndrome, a rare form of genetic epilepsy caused by mutations in the SCN1A gene. In addition to the commercial manufacturing build-out, the funding will also support a 2027 IND submission for ETX301, an AAV9-based vectorized microRNA gene therapy for post-amputation neuroma pain. Story

September 9—Solstice Oncology
Series: A
Amount: $225M
Investors: RA Capital Management, Canaan Partners, Forbion and others.

The Boston-based company licensed an Fc-enhanced cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) antibody, called porustobart, from China’s Harbour BioMed back when it was founded in February. The series A will be used to fund the phase 2 trial testing porustobart with Keytruda. The study is due to start enrolling this year for a readout in the second half of 2027. Solstice also plans to develop porustobart in another, as-yet-undisclosed indication. Story

September 9—TwoStep Therapeutics
Series: A
Amount: $62.5M
Investors: Insight Partners, Medical Excellence Capital, M Ventures (the venture capital arm of Merck KGaA), Pfizer Ventures, NFX, 2048 Ventures, Stanford University and others.

With a new pair of Big Pharma backers, TwoStep is looking to dance its lead peptide-drug conjugate into the clinic later this year for solid tumors. TS-104 combines TwoStep’s multi-targeting technique, a polyspecific integrin-binding peptide or PIP, with the potent chemo payload monomethyl auristatin E (MMAE). The company counts Carolyn Bertozzi, Ph.D., the Stanford chemist and 2022 Nobel Laureate, among its co-founders. Release

September 9—Tectora Therapeutics
Series: A
Amount: $55M
Investors: New Enterprise Associates and RA Capital Management.

The new immune disease-focused Tectora has spun out from Schrödinger with two early-stage small molecule programs. Tectora will partner with Schrödinger’s drug discovery experts and leverage Schrödinger’s computational platform to help advance these candidates to the clinic. The programs, SDGR-4594 and SDGR-8139, are currently in undisclosed indications but are products of Schrödinger’s computational platform. Story

September 9—Caspian Therapeutics
Series: N/A
Amount: $50M
Investors: BVF Partners, T1D Fund, Invus, Montanova, Eli Lilly and Company, Kura Oncology, members of Kura’s leadership team and several other biotech entrepreneurs.

The new Kura Oncology spinout will be focused on KO-7246, a highly selective menin inhibitor that Kura has billed as being “purpose-designed for chronic metabolic diseases.” A portion of the funding has also been earmarked to support development of another menin inhibitor aimed at diabetes and other cardiometabolic diseases. Story

September 8—BrainChild Bio
Series: A
Amount: $116M
Investors: Undisclosed private family fund and foundation, Seattle Children’s and WRF Capital

Three years after pediatric oncologist Michael Jensen, M.D., launched BrainChild Bio out of Seattle Children’s Hospital, the company has raised a series A round to support the completion of a pivotal phase 2 trial  for its lead candidate, BCB-276, in a childhood brainstem cancer called diffuse intrinsic pontine glioma (DIPG). Radiation is the current standard of care and is mostly palliative, so the company hopes to develop the first DIPG-specific treatment by taking T cells from patients, genetically modifying them to attack cancer then reinfusing them into the central nervous system. The biotech has a second program focused on glioblastoma, an aggressive brain cancer with a much larger patient pool that also includes adults, and plans to launch a phase 1 trial in that indication next year. Story

September 8—Moonwalk Biosciences
Series: B
Amount: $70M
Investors: Alpha Wave, YK Bioventures, Eli Lilly, Gaorong Ventures, Arch Venture Partners, Khosla Ventures and Future Ventures

Moonwalk Biosciences will deploy the funds to advance adipose-targeted RNA interference (RNAi) medicines for obesity and cardiometabolic diseases. After launching in 2024 with a $57 million series A round, the South San Francisco- and San Diego-based genomic biotech plans to use the latest funding to move the company’s lead obesity candidate, MW101, into the clinic late next year. The proceeds are also intended to support Moonwalk’s pipeline of tissue-targeted siRNA medicines and advance its discovery platform, which aims to selectively deliver siRNA therapeutics directly to adipose tissue, enabling precise modulation of novel, non-incretin pathways underlying obesity. Release

September 3—NeuShen Therapeutics
Series: B
Amount: $80M
Investors: B Capital, Legend Capital, Matrix Partners China, TruMed Investment, SSCI and Lilly Asia Ventures

The Shanghai and Boston-based biotech will use the funds to advance its clinical-stage, central nervous system-focused candidates, including a non-hallucinogenic 5-HT2A receptor partial agonist for treatment-resistant depression, as well as an M4 receptor positive allosteric modulator being evaluated for both schizophrenia and agitation associated with Alzheimer’s disease. There’s also a KCNQ2/3 channel opener for both focal onset seizures and major depressive disorder. Release

September 3—Superluminal Medicines
Series: B
Amount: $60M
Investors: BVF Partners L.P., Deep Track Capital, Perceptive Advisors, RA Capital Management, Insight Partners, NVIDIA, Catalio Capital Management, Eli Lilly and Company, Cooley and Gaingels.

The cash will supercharge Superluminal’s phase 1 plans for an MC4R agonist in development for genetic forms of obesity and hypothalamic obesity. The trial is expected to kick off later this year. The raise is also meant to help the Boston biotech build up its pipeline of specially crafted small molecules that target G protein-coupled receptors. Release

August

August 28—AusperBio
Series: C
Amount: $120M
Investors: RA Capital Management, HanKang Capital, Sherpa Capital, InnoPinnacle Fund, Qiming Venture Partners, YuanBio Venture Capital and CDH Investments.

The funds will be used to advance the company’s oligonucleotide therapy for chronic hepatitis B through phase 3 testing and hopefully on to commercialization. The Bay Area biotech’s lead candidate, dubbed AHB-137, is an unconjugated antisense oligonucleotide (ASO) designed to suppress production of viral hepatitis B protein, inhibit viral DNA replication and promote immune reactivation. The therapy is currently undergoing a late-stage study in China. Chronic hepatitis B, caused by the hepatitis B virus, affects nearly 296 million people worldwide. Story

August 18—Abcuro
Series: D
Amount: $66M
Investors: New Leaf Venture Partners, Bain Capital Life Sciences, Samsara BioCapital, Redmile Group, Mass General Brigham Ventures, RA Capital Management, Pontifax, Sanofi Ventures, Foresite Capital, NEA, Eurofarma Ventures, Kaitai Capital, Soleus Capital, Nancy Chang, Shang Bay, Rock Springs Capital.

Autoimmune disease-focused Abcuro will use the funds to support a new clinical study of ulviprubart, its leading monoclonal antibody targeting T cells, for the treatment of patients with less severe inclusion body myositis (IBM). In late March, Abcuro reported ulviprubart data in a phase 2/3 trial in a broader population of patients with IBM. Although the study did not reach statistical significance for slowing of the disease, the company noted a positive signal in a pre-specified subgroup of patients with less severe disease. Release

August 12—InduPro
Series: B
Amount: $77M
Investors: The Column Group, Vida Ventures, MRL Ventures Fund (the therapeutics-focused venture fund of Merck & Co., Inc.), Emerson Collective (advised by Yosemite), Euclidean Capital, Solasta Ventures, Sanofi and Eli Lilly and Company.

InduPro has assembled a syndicate of Big Pharma backers to push its lead cancer candidate IDP-001 through a phase 1 trial that just dosed its first patient. IDP-001 is a bispecific antibody-drug conjugate targeting EGFR and a novel tumor-associated proximity antigen (TAPA). The first-in-human trial is testing the molecule in advanced or metastatic squamous or non-squamous non-small cell lung cancer and other squamous solid tumors with disease progression. Release

August 11—Vaderis Therapeutics
Series: B
Amount: $152M
Investors: Life Sciences at Goldman Sachs Alternatives, TCGX, Omega Funds, EQT Life Sciences, Perceptive Advisors, Kalehua Capital, Medicxi and Droia.

The new cash will propel the Swiss biotech’s AKT inhibitor through phase 3 with the aim of bringing the first treatment for a rare blood vessel disorder to market. The Basel-based company has just launched a late-stage study to evaluate the once-daily oral drug, called engasertib, in patients with hereditary hemorrhagic telangiectasia. There are currently no approved therapies for the rare genetic vascular disorder, which affects one in every 3,800 people. Story

August 11—Epicrispr Biotechnologies
Series: C
Amount: $90M
Investors: Octagon Capital, Janus Henderson Investors, Fidelity Management & Research Company, Cormorant Asset Management, Duquesne Family Office, Sanofi Ventures, funds managed by abrdn Inc., Angelini Ventures, Readout Capital and existing investors.

The funds position the biotech to advance a pipeline of epigenetic medicines led by an early-phase facioscapulohumeral muscular dystrophy (FSHD) prospect. San Francisco-based Epicrispr began a phase 1/2 trial of the FSHD drug candidate, EPI-321, last year. A recent look at data from the trial showed increases in lean muscle mass in three patients with FSHD, a rare muscle degeneration disease. Story

August 11—Infinimmune
Series: A
Amount: $75M
Investors: Regeneron Ventures, Playground Global, RA Capital Management, Goldcrest Capital, Forge Life Science Partners, Godfrey Capital, Wild Tree Ventures, Merck Global Health Innovation Fund, Everbright Biofund, Civilization Ventures and Pear VC.

The antibody upstart will use the raise to push two eczema candidates into the clinic next year. IFX-101 is designed to hit interleukin-22, which has never been drugged before, while IFX-201 targets interleukin-13, which is also a target of Regeneron and Sanofi’s Dupixent. Story

August 6—LifeMine Therapeutics
Series: E
Amount: $188M
Investors: Milky Way Investments**,** Bezos Expeditions, Gates Frontier, RA Capital Management, Google Ventures, LoLa Capital Partners, GSK, Invus and ARCH Venture Partners

After layoffs last year, LifeMine got back on track by convincing Jeff Bezos, Bill Gates and other investors to back its latest $188 million funding round, aimed at advancing the clinical development of LIFE-001, an immunosuppressant designed to prevent the immune system from rejecting transplanted organs. LifeMine plans to launch a phase 2 kidney transplant study and a phase 1b islet cell transplant study for the treatment. Story

August 5—Expedition Therapeutics
Series: B
Amount: $115M
Investors: General Atlantic, RA Capital, Vivo Capital, Sofinnova Investments, Novo Holdings, Forbion, Dawn Biopharma, Adage Capital Management, Balyasny Asset Management, Logos Capital, Sanofi Ventures, BVF Partners and Venrock Healthcare Capital Partners.

San Francisco-based Expedition will use the oversubscribed financing to advance its lead DPP1 inhibitor, EXPD-101, through phase 2 development after recently initiating the trial in patients with chronic obstructive pulmonary disease. The infusion of series B cash will not only finance the study, but also provide “dry powder to continue to pursue other assets to bring into our portfolio and continue to fund our own proprietary discovery efforts,” Expedition CEO Yi Larson told Fierce. Story

July

July 31—Ratio Therapeutics
Series: C
Amount: $70M
Investors: Duquesne Family Office, Bristol Myers Squibb, Catalio Capital Management, Eli Lilly and Company and Wasatch Group.

The Boston radiopharma will use the funds to advance a phase 1/2 trial of lead asset RTX-2358, which uses an isotope of actinium for advanced sarcomas. The cash will also go towards building up Ratio’s oncology pipeline and scaling its manufacturing capabilities. Release

July 22—Crystalys Therapeutics
Series: B
Amount: $130M
Investors: Frazier Life Sciences, Wellington Management, HBM Healthcare Investments, Soleus Capital, Cormorant Asset Management, Trails Edge Capital Partners, Pivotal bioVenture Partners and KCap Biotechnology Fund, Novo Holdings, SR One, Catalys Pacific, Perceptive Xontogeny Venture Funds, Lightstone Ventures, AN Venture Partners, funds managed by abrdn Inc., KB Investments, Pontifax, Longwood Fund, Alexandria Venture Investments, Wedbush Healthcare Partners and Prebys Ventures Fund. 

Crystalys Therapeutics has raised $130 million in series B financing less than a year after emerging from stealth with an impressive $205 million series A round in September 2025. The proceeds will support two ongoing, registration-directed phase 3 trials, as well as the phase 2 Amethyst study. Crystalys also plans to use the money to prepare for dotinurad’s potential commercialization. The financing is expected to extend the company’s runway through multiple clinical and regulatory milestones. CEO James Mackay described dotinurad as an extremely “de-risked molecule” because it has already been approved in several Asian markets. The drug, originally developed by Japanese drugmaker Fuji Yakuhin, is approved in Japan, China, the Philippines, Taiwan and Thailand. Story.

July 15—AdvanCell
Series: D
Amount: $315M
Investors: Ally Bridge Group, Alpha Wave, Bain Capital Life Sciences, Fidelity Management & Research Company, funds and accounts advised by T. Rowe Price Associates, Inc., a leading sovereign wealth fund, Eventide Asset Management, Velosity Capital, Morningside, Eli Lilly and Company, SV Health Investors, Sanofi Ventures, Abingworth, SymBiosis, Tenmile, Brandon Capital, Piper Heartland, Catalio Capital Management, Proto Axiom, Time BioVentures and others.

Less than a month after locking down a lease for a new U.S. headquarters, radiotherapy outfit AdvanCell is poised to push its lead prostate cancer candidate into phase 3 development with its new cash haul. Unlike other peer drugs, AdvanCell’s prostate cancer prospect, ADVC001, uses a lead isotope rather than radium or actinium. AdvanCell’s series D will also be put to use on further scaling up manufacturing, including in the U.S., in advance of the eventual phase 3 trial. Story

July 14—Draig Therapeutics
Series: B
Amount: $65M
Investors: Deep Track Capital, Janus Henderson Investors, Marshall Wace, British Business Bank and Jefferson Life Sciences.

The Welsh biotech will use the fresh funds to propel its neurological pipeline, which is led by DT-101. The AMPA receptor potentiator is currently in a number of phase 2 trials for major depressive disorder, and the company said the drug has shown “encouraging safety, tolerability and target engagement data and displays a pulsatile pharmacokinetic profile which gives us real conviction in its potential.” Draig also has a pair of GABA modulators that it is aiming to take into the clinic. Release

July 14—Chai Discovery
Series: C
Amount: $400M
Investors: Index Ventures, Kleiner Perkins, Sequoia Capital, Dimension, Bain Capital Ventures, Battery Ventures, Baillie Gifford, BDT & MSD, Sapphire Ventures, Avra Capital, Thrive Capital, OpenAI, Oak HC/FT, Menlo Ventures, General Catalyst, Glade Brook, Avenir, Lachy Groom, and Yosemite.

Chai Discovery continued its whirlwind emergence, closing its third financing round in less than a year to bring its total funding haul above $600 million. The San Francisco-based company develops AI models that have enticed the likes of Lilly, Pfizer and Novartis this year. The deals helped Chai raise its biggest round yet, with partners at Index Ventures, Kleiner Perkins and Sequoia Capital all citing real-world use of the startup’s AI by leading drugmakers to explain their participation in the series C. Story

July 13—Drug Farm
Series: D
Amount: $55M
Investors: Shanghai Pudong Leading Area Investment Center, Shanghai Puxing Collaborative Private Equity Fund Partnership Enterprise, Tukar Capital, Fuzhou Xinhe Fund, Shenzhen Luohu Donghai Chempartner Investment Fund, Keyuan Pharma, BioVeda China Fund, YD Capital, Jiashan State VC, Detong Capital, Wedo Capital and Biometas.

Drug Farm will plow the fresh funds into DF-003, an ALPK1 inhibitor that’s going through a phase 3 study for an autoinflammatory genetic disorder called ROSAH syndrome, as well as a phase 2-stage ALPK1 agonist immunomodulator called DF-006 that’s being developed for both hepatitis B and hepatocellular cancer. The Shanghai-based company is also assessing DF-006 in combination with Amoytop’s Pegbing, which is approved in China as a functional cure for hepatitis B virus. Release

July 9—MindRank AI
Series: B
Amount: $52M
Investors: “A group of institutional and healthcare funds.”

The Shanghai-based company will use the cash to advance its so-called Molecule Arts Platform (MAP), which it touts as a “unified R&D system designed to support the discovery and development of new medicines.” The money will also be spent on pushing forward with the company’s pipeline, which is led by an oral small-molecule GLP-1 receptor agonist that has already entered phase 3 trials in China. Release

July 2—Celea Therapeutics
Series: “Debut financing”
Amount: $180M
Investors: RA Capital Management, Leaps by Bayer, PureTech Health, a “large, U.S.-based healthcare-focused fund” and a “leading sovereign wealth fund”

Almost a year after London-listed Celea was founded by PureTech to take forward its promising idiopathic pulmonary fibrosis candidate deupirfenidone, the hub-and-spoke biotherapeutics company has touted what it describes as one of the largest debut financings of 2026 for its spin-out. The cash will be used to take the antifibrotic into a head-to-head phase 3 study against the commonly used IPF drug pirfenidone, which is pencilled in for the third quarter. While approved antifibrotics for IPF slow disease progression, PureTech and Celea hope that deupirfenidone will continue to demonstrate the potential to stabilize lung function decline to levels comparable to normal aging. Release

June

June 25—Lycia Therapeutics
Series: D
Amount: $75M
Investors: Janus Henderson Investors, Balyasny Asset Management, Adage Capital Management, HBM Healthcare Investments, OrbiMed, Eli Lilly, Franklin Templeton, Invus, RTW Investments and Venrock Healthcare Capital Partners.

Autoimmune, inflammatory and allergic disease biotech Lycia has pulled down an oversubscribed series D from a suite of big-name investors, including Eli Lilly. The biotech plans to use the funds to support LCA-0061, which is designed to deplete immunoglobulin E for allergic diseases, and LCA-0321, a LYTAC degrader designed to selectively deplete thyroid-stimulating hormone receptor autoantibodies for Graves’ disease. Alongside the news of the fundraise, Lycia said it brought on Amy Bachrodt as chief financial officer and promoted Karen Flick to general counsel. Release

June 25—Oblenio Bio
Series: B
Amount: $62M
Investors: Pfizer Ventures, Deep Track Capital, GV and Aditum Bio.

After its founding two years ago, Oblenio Bio has completed an oversubscribed series B fundraise meant to push its trispecific T-cell engager, LBL‑051, into clinical testing. The candidate is licensed from China’s Leads Biolabs and works by targeting BCMA, CD19 and CD3. The company didn’t disclose the indication it plans to pursue in testing, only noting that the drug is “designed to reset the immune system in patients with severe autoimmune diseases.” Release

June 24—Ollin Biosciences
Series: B
Amount: $330M
Investors: TCGX, ARCH Venture Partners, a16z Bio+Health, Blackstone Multi-Asset Investing, Commodore Capital, Canada Pension Plan Investment Board (CPP Investments), RA Capital Management, accounts advised by T. Rowe Price Investment Management, Inc., a leading sovereign wealth fund, Mubadala Capital and Monograph Capital.

Half a year after toppling Genentech’s eye medicine giant Vabysmo in an early trial, Texas biotech Ollin Biosciences has lassoed a $330 million series B to push its winning contender through a multi-trial phase 3 gauntlet. The company plans to launch its VEGF/Ang2 bispecific antibody OLN324 into at least three phase 3 trials. Story

June 24—RQ Bio
Series: A
Amount: $115M
Investors: Frazier Life Sciences, EQT Life Sciences, Forbion, Monograph, Wellington Management, LifeArc Ventures, Oxford Science Enterprises and the University of Oxford.

After its founding several years ago by U.K. scientists and LifeArc Ventures, RQ Bio is making a splash with a $115 million series A. The U.K. biotech plans to use the funds to propel its lead program, RQB01, into clinical testing next year. The candidate is a long-acting antiviral for flu prevention featuring characteristics that RQ believes could improve upon the status quo for vulnerable individuals. The company also plans to use the money to “advance our proprietary antibody discovery approach towards a pipeline of assets for prophylaxis of respiratory viral diseases.” Story

June 23—Osanni Bio
Series: B
Amount: $190M
Investors: Patient Square Capital, Horowitz Group, Invus Opportunities and the Retinal Degeneration Fund.

Osanni launched three years ago with a $27 million series A and has kept purposefully quiet ever since. The new raise will power clinical development of a lead candidate for dry age-related macular degeneration and also help propel six other preclinical assets into the clinic. Originally conceived with an eye disease focus, the biotech has since expanded to seven pipeline programs across ophthalmology, cardiology and cancer. Story

June 23—Serapha Bio
Series: A
Amount: $230M
Investors: RA Capital Management, RTW Investments, Janus Henderson Investors, Decheng Capital, Vivo Capital, Casdin Capital, LifeSci Venture Partners, Logos Capital, Balyasny Asset Management and Eventide Asset Management.

Serapha has launched through a reverse merger with Boundless Bio and the licensing of an alpha-1-antitrypsin deficiency candidate from Chinese biotech YolTech Therapeutics. The fundraise consists of a $138 million series A plus $92 million in additional funding expected to close upon the finalization of the merger. Serapha expects this haul will propel its operations into the second half of 2029, enabling it to complete phase 2 testing and start phase 3. Story

June 22—Nura Bio
Series: B
Amount: $73.8M
Investors: The Column Group, Euclidean Capital, Samsara BioCapital and Sanofi Ventures.

The Bay Area biotech will use the fundraise to power the phase 1b/2a study of oral SARM1 inhibitor NB-4746 for amyotrophic lateral sclerosis, which recently began dosing. NB-4746 is designed to penetrate into the brain and prevent axon degeneration, protecting neurons from degrading. The company plans to wrap up a phase 1a trial for another SARM1 inhibitor, NB-9402, later this year. Release

June 18—Memento Medicines
Series: A
Amount: $93M
Investors: Forbion, RA Capital Management, Avego BioScience Capital, Sanofi Ventures and Samsara BioCapital.

Memento Medicines has launched with big-name backers and a quest to shake up the diabetic macular edema and neovascular age-related macular degeneration fields. Alongside the fundraise, the company revealed that it has licensed MMT-205, which it describes as a “a potential best-in-class bispecific antibody which activates Tie2 and inhibits VEGF.” Memento is the fifth subsidiary of Sera Medicines, a biotech accelerator formed in collaboration with RA Capital back in 2023. With the funds, the company plans to execute IND-enabling studies, eying potential clinical trial initiations next year. Release

June 17—Triveni Bio
Series: C
Amount: $65M
Investors: Ascenta Capital and Janus Henderson Investors, with participation from Deep Track Capital and existing investors. 

Clinical-stage biotech Triveni Bio has raised a $65 million series C round to support TRIV-573, a bispecific designed to fight the cause of atopic dermatitis by inhibiting KLK5/7 and Th2 cytokine IL-13. It initiated its first-in-human clinical studies in the past few weeks and is expected to go into an atopic dermatitis phase 2 clinical proof-of-concept study later this year. In a statement, Triveni CEO Vishal Patel, Ph.D., said the financing “enables us to disrupt the status quo in atopic dermatitis.” Release

June 10—SonoThera
Series: B
Amount: $125M
Investors: Vida Ventures, ARK Invest, CureDuchenne Ventures, Leaps by Bayer, Otsuka Pharmaceutical, SymBiosis, UCB Ventures SA, Vivo Capital, ARCH Venture Partners, Alexandria Venture Investments, Duquesne Family Office, Illumina Ventures, Johnson & Johnson Innovation, Medical Excellence Capital, RA Capital and Vertex Ventures HC.

The Bay Area biotech will use the raise to push its lead candidate for Duchenne muscular dystrophy and an autosomal dominant polycystic kidney disease program into the clinic. The company has secured significant Big Pharma interest due to the potential for SonoThera’s tech to solve long-standing problems with traditional delivery systems and bring genetic medicines to bigger patient populations, CEO Kenneth Greenberg, Ph.D., told Fierce. Story

June 10—Ethyreal Bio
Series: A and B
Amount: $101M
Investors: The Series A was co-led by Atlas Venture and Medicxi Ventures, alongside Nandi Life Sciences and Checkpoint Capital. The Series B included all Series A investors and was led by Avoro Capital.

Ethyreal exited stealth with $101 million accrued across series A and B rounds, joining the queue of companies preparing to challenge Amgen’s Tepezza. A first-in-human trial of the asset, ETHY-001, is scheduled to start this year. Ethyreal is developing the drug candidate in thyroid eye disease and Graves’ disease. Story

June 8—City Therapeutics
Series: B
Amount: $99.5M
Investors: Viking Global Investors, Sofinnova Investments, Casdin Capital, NYBC Ventures, ARCH Venture Partners, Fidelity Management & Research Company, Invus, Slate Path Capital, Rock Springs Capital, Regeneron Ventures, AN Ventures and others.

Looking to spark an antibody-like revolution for RNA interference medicines, City Therapeutics will use its nearly $100 million series B to fund a clinical push for its lead anticoagulant and power further development of its foundational platform, which aims to engineer smaller and more flexible RNA molecules. Story

June 4—Ona Therapeutics
Series: B
Amount: $86.6M
Investors: Columbus Venture Partners, Mérieux Equity Partners, COFIDES, Korys, Alta Life Sciences, Asabys Partners, Bpifrance, CDTI, FundPlus NV and Ysios Capital.

Spanish biotech Ona Therapeutics has raised an $86.6 million series B round to support its antibody-drug conjugate (ADC) program. It’s lead candidate aims to address treatment-resistant tumor biology and is focused on breast cancer. The funds will also support a second colorectal ADC asset and move it toward first-in-human studies. The company deploys a proprietary patient-driven target discovery platform to identify novel tumor-specific antigens and epitopes that enable highly efficient internalization and targeted payload delivery to cancer cells. Release

June 2—Contraline
Series: B
Amount: $92.5M
Investors: BVF Partners, RA Capital Management, Google Ventures, Lumira Ventures, Invus and others.

Five years after a $10.7 million series A fundraise when it was a medical device company, Contraline has transformed into a clinical stage biopharma and raised an additional $92.5 million. The series B round will support its late-stage development of NES/T Gel, a reversible male contraceptive designed to suppress sperm production while maintaining physiological testosterone levels. The treatment recently completed a global Phase 2b clinical trial, and encouraging data led the company to plan a phase 3 study for 2027. Release

June 2—NewLimit
Series: C
Amount: $435M
Investors: Founders Fund, Thrive Capital, Greenoaks, Quiet Capital, Kleiner Perkins, Abstract, Nat Friedman/Daniel Gross, Valor Equity Partners, Eli Lilly Ventures, Human Capital and others.

After closing a $130 million round last May with the expectation that it would take several years to develop a drug ready for clinical testing, the longevity biotech instead found that a promising compound jumped out of its data at the end of last year. NewLimit plans to push this lead candidate into the clinic for fatty liver diseases next year, and is also working on candidates that de-age blood vessel cells and T cells. Story 

May

May 19—Accro Bioscience
Series: C
Amount: $50M
Investors: OrbiMed, TCG Crossover, LAV, Cenova Capital, Shenzhen Capital Group and Oriza Holdings.

Based in Suzho…

Leave a Reply

Your email address will not be published. Required fields are marked *